1. Home
  2. SLN vs SMC Comparison

SLN vs SMC Comparison

Compare SLN & SMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLN
  • SMC
  • Stock Information
  • Founded
  • SLN 1994
  • SMC 2009
  • Country
  • SLN United Kingdom
  • SMC United States
  • Employees
  • SLN N/A
  • SMC N/A
  • Industry
  • SLN Biotechnology: Pharmaceutical Preparations
  • SMC
  • Sector
  • SLN Health Care
  • SMC
  • Exchange
  • SLN Nasdaq
  • SMC NYSE
  • Market Cap
  • SLN 352.2M
  • SMC 398.9M
  • IPO Year
  • SLN N/A
  • SMC 2012
  • Fundamental
  • Price
  • SLN $6.47
  • SMC $35.29
  • Analyst Decision
  • SLN Strong Buy
  • SMC
  • Analyst Count
  • SLN 4
  • SMC 0
  • Target Price
  • SLN $61.50
  • SMC N/A
  • AVG Volume (30 Days)
  • SLN 959.2K
  • SMC 77.0K
  • Earning Date
  • SLN 11-14-2024
  • SMC 02-05-2025
  • Dividend Yield
  • SLN N/A
  • SMC N/A
  • EPS Growth
  • SLN N/A
  • SMC N/A
  • EPS
  • SLN N/A
  • SMC N/A
  • Revenue
  • SLN $21,773,221.00
  • SMC $450,857,000.00
  • Revenue This Year
  • SLN N/A
  • SMC N/A
  • Revenue Next Year
  • SLN $104.98
  • SMC N/A
  • P/E Ratio
  • SLN N/A
  • SMC N/A
  • Revenue Growth
  • SLN N/A
  • SMC 7.80
  • 52 Week Low
  • SLN $5.81
  • SMC $15.56
  • 52 Week High
  • SLN $27.72
  • SMC $40.75
  • Technical
  • Relative Strength Index (RSI)
  • SLN 27.24
  • SMC 42.07
  • Support Level
  • SLN $6.06
  • SMC $34.30
  • Resistance Level
  • SLN $8.88
  • SMC $38.14
  • Average True Range (ATR)
  • SLN 0.72
  • SMC 1.07
  • MACD
  • SLN 0.22
  • SMC -0.30
  • Stochastic Oscillator
  • SLN 22.52
  • SMC 32.07

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.

About SMC SUMMIT MIDSTREAM CORPORATION

Summit Midstream Corp is a value-driven corporation focused on developing, owning and operating midstream energy infrastructure assets strategically located in unconventional resource basins, primarily shale formations, in the continental U.S. It currently operates natural gas, crude oil and produced water gathering systems in four unconventional resource basins: the Williston Basin in North Dakota, which includes the Bakken and Three Forks shale formations; the Denver-Julesburg Basin, which includes the Niobrara and Codell shale formations in Colorado and Wyoming; the Fort Worth Basin in Texas, which includes the Barnett Shale formation; and the Piceance Basin in Colorado, which includes the liquids-rich Mesaverde formation as well as the emerging Mancos and Niobrara Shale formations.

Share on Social Networks: